5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole | |
---|---|
Trade Name | |
Orphan Indication | Duchenne muscular dystrophy |
USA Market Approval | USA |
USA Designation Date | 2011-11-22 00:00:00 |
Sponsor | Summit Corporation plc;91 Milton Park, Oxfordshire OX14 4RY; |